Inmode Ltd (INMD)

$17.6

-0.1

(-0.56%)▲

Market is closed - opens 7 PM, 26 Jul 2024

Performance

  • $17.43
    $18.05
    $17.60
    downward going graph

    0.97%

    Downside

    Day's Volatility :3.41%

    Upside

    2.47%

    downward going graph
  • $16.44
    $48.25
    $17.60
    downward going graph

    6.59%

    Downside

    52 Weeks Volatility :65.93%

    Upside

    63.52%

    downward going graph

Returns

PeriodInmode LtdSector (Health Care)Index (Russel 2000)
3 Months
2.68%
6.5%
0.0%
6 Months
-24.3%
7.1%
0.0%
1 Year
-60.91%
9.8%
0.0%
3 Years
-67.77%
14.2%
-20.2%

Highlights

Market Capitalization
1.5B
Book Value
$9.65
Earnings Per Share (EPS)
2.11
PE Ratio
8.39
PEG Ratio
2.9
Wall Street Target Price
21.2
Profit Margin
38.84%
Operating Margin TTM
22.53%
Return On Assets TTM
13.83%
Return On Equity TTM
25.54%
Revenue TTM
466.3M
Revenue Per Share TTM
5.56
Quarterly Revenue Growth YOY
-24.3%
Gross Profit TTM
380.8M
EBITDA
173.4M
Diluted Eps TTM
2.11
Quarterly Earnings Growth YOY
-0.4
EPS Estimate Current Year
1.94
EPS Estimate Next Year
2.19
EPS Estimate Current Quarter
0.44
EPS Estimate Next Quarter
0.5

Analyst Recommendation

Buy
    66%Buy
    33%Hold
    0
    0%Sell
Based on 12 Wall street analysts offering stock ratings for Inmode Ltd(by analysts ranked 0 to 5 stars)
Based on 12 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
8
8
8
Hold
4
4
4
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 20.45%

Current $17.60
Target $21.20

Company Financials

FY18Y/Y Change
Revenue
100.2M
↑ 87.37%
Net Income
22.4M
↑ 153.67%
Net Profit Margin
22.33%
↑ 5.83%
FY19Y/Y Change
Revenue
156.4M
↑ 56.11%
Net Income
61.1M
↑ 173.32%
Net Profit Margin
39.11%
↑ 16.78%
FY20Y/Y Change
Revenue
206.1M
↑ 31.81%
Net Income
75.0M
↑ 22.71%
Net Profit Margin
36.4%
↓ 2.71%
FY21Y/Y Change
Revenue
357.6M
↑ 73.49%
Net Income
165.0M
↑ 119.87%
Net Profit Margin
46.14%
↑ 9.74%
FY22Y/Y Change
Revenue
454.3M
↑ 27.05%
Net Income
161.5M
↓ 2.09%
Net Profit Margin
35.56%
↓ 10.58%
FY23Y/Y Change
Revenue
492.0M
↑ 8.32%
Net Income
197.9M
↑ 22.54%
Net Profit Margin
40.22%
↑ 4.66%
Q4 FY22Q/Q Change
Revenue
133.6M
↑ 10.18%
Net Income
37.7M
↓ 22.71%
Net Profit Margin
28.23%
↓ 12.01%
Q1 FY23Q/Q Change
Revenue
106.1M
↓ 20.59%
Net Income
40.5M
↑ 7.42%
Net Profit Margin
38.19%
↑ 9.96%
Q2 FY23Q/Q Change
Revenue
136.1M
↑ 28.29%
Net Income
55.7M
↑ 37.59%
Net Profit Margin
40.95%
↑ 2.76%
Q3 FY23Q/Q Change
Revenue
123.1M
↓ 9.53%
Net Income
46.5M
↓ 16.52%
Net Profit Margin
37.79%
↓ 3.16%
Q4 FY23Q/Q Change
Revenue
126.8M
↑ 2.98%
Net Income
55.2M
↑ 18.58%
Net Profit Margin
43.51%
↑ 5.72%
Q1 FY24Q/Q Change
Revenue
80.3M
↓ 36.68%
Net Income
23.7M
↓ 57.05%
Net Profit Margin
29.52%
↓ 13.99%
FY18Y/Y Change
Total Assets
81.1M
↑ 105.51%
Total Liabilities
36.4M
↑ 82.0%
FY19Y/Y Change
Total Assets
218.4M
↑ 169.42%
Total Liabilities
38.6M
↑ 6.05%
FY20Y/Y Change
Total Assets
295.8M
↑ 35.43%
Total Liabilities
40.3M
↑ 4.42%
FY21Y/Y Change
Total Assets
478.5M
↑ 61.8%
Total Liabilities
62.7M
↑ 55.73%
FY22Y/Y Change
Total Assets
644.4M
↑ 34.66%
Total Liabilities
89.8M
↑ 43.12%
FY23Y/Y Change
Total Assets
863.3M
↑ 33.97%
Total Liabilities
75.9M
↓ 15.45%
Q4 FY22Q/Q Change
Total Assets
644.4M
↑ 11.3%
Total Liabilities
89.8M
↑ 27.04%
Q1 FY23Q/Q Change
Total Assets
669.6M
↑ 3.91%
Total Liabilities
66.6M
↓ 25.79%
Q2 FY23Q/Q Change
Total Assets
734.1M
↑ 9.63%
Total Liabilities
67.9M
↑ 1.94%
Q3 FY23Q/Q Change
Total Assets
793.5M
↑ 8.1%
Total Liabilities
70.0M
↑ 3.1%
Q4 FY23Q/Q Change
Total Assets
863.3M
↑ 8.79%
Total Liabilities
75.9M
↑ 8.4%
Q1 FY24Q/Q Change
Total Assets
891.7M
↑ 3.3%
Total Liabilities
76.3M
↑ 0.51%
FY18Y/Y Change
Operating Cash Flow
36.9M
↑ 152.49%
Investing Cash Flow
-29.7M
↑ 423.21%
Financing Cash Flow
186.0K
↓ 89.58%
FY19Y/Y Change
Operating Cash Flow
62.2M
↑ 68.64%
Investing Cash Flow
-112.5M
↑ 278.13%
Financing Cash Flow
70.2M
↑ 37627.42%
FY20Y/Y Change
Operating Cash Flow
79.2M
↑ 27.36%
Investing Cash Flow
-43.3M
↓ 61.49%
Financing Cash Flow
-12.4M
↓ 117.73%
FY21Y/Y Change
Operating Cash Flow
174.9M
↑ 120.74%
Investing Cash Flow
-160.1M
↑ 269.72%
Financing Cash Flow
-15.0M
↑ 20.74%
FY22Y/Y Change
Operating Cash Flow
181.6M
↑ 3.83%
Investing Cash Flow
-109.5M
↓ 31.62%
Financing Cash Flow
-41.1M
↑ 173.5%
Q4 FY22Q/Q Change
Operating Cash Flow
57.2M
↑ 25.36%
Investing Cash Flow
-38.3M
↓ 31.81%
Financing Cash Flow
637.0K
↑ 15.82%
Q1 FY23Q/Q Change
Operating Cash Flow
21.1M
↓ 63.06%
Investing Cash Flow
-27.6M
↓ 28.01%
Financing Cash Flow
1.7M
↑ 162.64%
Q2 FY23Q/Q Change
Operating Cash Flow
53.0M
↑ 151.03%
Investing Cash Flow
-69.8M
↑ 153.38%
Financing Cash Flow
827.0K
↓ 50.57%
Q3 FY23Q/Q Change
Operating Cash Flow
41.4M
↓ 21.8%
Investing Cash Flow
-69.8M
↑ 0.0%
Financing Cash Flow
2.7M
↑ 229.99%

Technicals Summary

Sell

Neutral

Buy

Inmode Ltd is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Inmode Ltd
Inmode Ltd
1.68%
-24.3%
-60.91%
-67.77%
159.4%
Stryker Corporation
Stryker Corporation
-3.84%
5.16%
12.86%
24.25%
52.69%
Boston Scientific Corp.
Boston Scientific Corp.
-3.68%
21.48%
41.72%
68.89%
76.47%
Edwards Lifesciences Corp.
Edwards Lifesciences Corp.
-34.8%
-18.49%
-34.85%
-45.17%
-15.86%
Abbott Laboratories
Abbott Laboratories
1.03%
-5.4%
-7.12%
-11.35%
20.75%
Medtronic Plc
Medtronic Plc
-1.99%
-9.34%
-13.21%
-38.74%
-23.49%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Inmode Ltd
Inmode Ltd
8.39
8.39
2.9
1.94
0.26
0.14
NA
9.65
Stryker Corporation
Stryker Corporation
38.91
38.91
2.92
11.95
0.19
0.07
0.01
50.33
Boston Scientific Corp.
Boston Scientific Corp.
63.22
63.22
1.8
2.37
0.09
0.05
NA
13.16
Edwards Lifesciences Corp.
Edwards Lifesciences Corp.
36.4
36.4
5.19
2.76
0.22
0.12
NA
12.35
Abbott Laboratories
Abbott Laboratories
33.84
33.84
5.99
4.66
0.15
0.06
0.02
22.31
Medtronic Plc
Medtronic Plc
28.97
28.97
1.52
5.2
0.07
0.04
0.04
38.29
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Inmode Ltd
Inmode Ltd
Buy
$1.5B
159.4%
8.39
38.84%
Stryker Corporation
Stryker Corporation
Buy
$129.7B
52.69%
38.91
16.03%
Boston Scientific Corp.
Boston Scientific Corp.
Buy
$114.3B
76.47%
63.22
12.05%
Edwards Lifesciences Corp.
Edwards Lifesciences Corp.
Buy
$52.4B
-15.86%
36.4
23.74%
Abbott Laboratories
Abbott Laboratories
Buy
$186.6B
20.75%
33.84
13.65%
Medtronic Plc
Medtronic Plc
Buy
$102.5B
-23.49%
28.97
11.36%

Insights on Inmode Ltd

  • Decreasing Revenue

    Revenue is down for the last 2 quarters, 126.78M → 80.28M (in $), with an average decrease of 36.7% per quarter

  • Decreasing Net Profit

    Netprofit is down for the last 2 quarters, 55.16M → 23.69M (in $), with an average decrease of 57.1% per quarter

  • Vs BSX

    In the last 1 year, Boston Scientific Corp. has given 41.7% return, outperforming this stock by 102.6%

  • Vs BSX

    In the last 3 years, Boston Scientific Corp. has given 68.9% return, outperforming this stock by 136.7%

Institutional Holdings

  • BlackRock Inc

    7.37%

  • Fidelity International Ltd

    4.02%

  • Meitav Dash Investments Ltd

    2.27%

  • State Street Corporation

    2.23%

  • LSV Asset Management

    2.22%

  • Renaissance Technologies Corp

    2.19%

Company Information

inmode offers the most exciting and effective aesthetic solutions with fractora, forma/plus, lumeccca, diolaze and bodyfx. fractora: bipolar radio-frequency fractional treatment for superior improvements in texture, wrinkles, acne scars and contraction. lumecca: broad spectrum pulsed light for rejuvenation of photo-damaged skin in a wide variety of skin types. diolaze: ultra fast diode hair removal featuring simultaneous 3pc (pre, parallel, and post cooling) technology and state of the art pulsing and power. bodyfx: non-invasive body contouring for buttocks, abdomen, flanks and thighs with a.c.e. technology

Organization
Inmode Ltd
Employees
581
CEO
Mr. Yair Malca
Industry
Health Technology

Discover More

FAQs